Clinical Trials Logo

Clinical Trial Summary

The study will investigate the safety and effectiveness of daily post surgical scar management, using a moisture-balancing base product containing different amounts of a novel (NCE) antifibrogenic compound FS2, a natural metabolite of the kynurenine pathway. Results of recent peer-reviewed, pre-clinical evidence warrant further investigation to validate therapeutic scar preventive efficacy of topically administered/delivered FS2. There are no known safety concerns with current product formulations. Recent Phase I clinical safety and tolerability data further support continuation of the research proposed in this study.


Clinical Trial Description

Study Arms (Investigational Conditions):

Total of 6, categorized by type of wound and treatment allocation.

Description of Study Arms:

The quality of tissue repair and scarring will be evaluated in two different, bisected post-surgical sites on the same Participant. Each wound site represents a Study Arm. Each wound site will receive two treatments, one of which is always a vehicle. In total the two wound types provide a total of 6 Study Arms for statistical analysis.

Arm 1 / Wound Type 1 (skin grafted wounds: 3-treatment groups): The wound site (injury) that requires skin grafting surgery to remove normal, uninjured skin from the same Participant to cover and repair a deep wound (a "skin graft").

Arm 2 / Wound Type (donor skin graft harvest site; 3-treatment groups): A surgical wound where a piece of normal skin is removed at uniform depth using a dermatome to harvest a skin graft ("skin graft harvest site").

The bisected wound site is randomly assigned either a control or FS2 cream treatment.

Treatment Groups: Each wound site will be used to investigate and compare three different treatments. Participants will apply the investigated treatments ("IP") as directed to allocated bisected sections of the skin grafted wound and donor wound site for 90 days. Follow-on assessments will be conducted with additional study visits on Days 180 and 270 (study endpoint).

There are four (4) differently labelled products as follows:

Treatment-1 (IP1) A single, daily application of a moisturizing cream-base.

Treatment-2 (IP2) A single, daily application of a moisturizing cream-base with FS2 (0.50% w/w).

Treatment-3 (IP3) A single, daily application of a moisturizing cream-base with FS2 (0.25% w/w). IP3 will have two different product labels to conceal the identity of the vehicle.

Control-cream (IP1), and treatments IP2 and IP3 each containing 0.50%w/w or 0.25%w/w FS2 respectively, will be topically applied to designated treatment sites once per day for a period of 90 days. Investigator and participant will be blinded from both identity of treatment product and randomized location. Each participant will be provided a different cream for each bisected-site for a total of four (4) differently labelled creams; two for the donor site, and two for the skin grafted site. Participants will discuss and be informed/reminded at each visit about study design, responsibilities, possible adverse events, proper daily wound care and cream application methods. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04186273
Study type Interventional
Source University of British Columbia
Contact Anthony Papp, MD, PhD
Phone 1.778.362.0161
Email anthony.papp@gmail.com
Status Recruiting
Phase Phase 2
Start date December 5, 2019
Completion date March 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT01706848 - Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound N/A
Recruiting NCT01177358 - Botox in the Healing of Surgical Wounds of the Neck Phase 2
Terminated NCT01459666 - Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Phase 4
Completed NCT00970671 - Treatment of Surgical Scars Using the Pulsed Dye Laser N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Completed NCT05293652 - Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar N/A
Recruiting NCT03406143 - Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration N/A
Completed NCT05527756 - Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery
Completed NCT02886988 - Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection Phase 2/Phase 3
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Recruiting NCT05408117 - Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color N/A
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Terminated NCT02520557 - An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
Not yet recruiting NCT04621994 - Cesarean Wound Closure: Dermabond Versus Steri Strips N/A
Withdrawn NCT03395678 - Acne Scarring in Skin of Color: Laser vs Microneedling N/A
Completed NCT02744950 - Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs N/A
Not yet recruiting NCT01005992 - Fractional Photothermolysis for the Treatment of Burn Scars Phase 1
Completed NCT04870008 - Aesthetic Outcome of Running Cuticular Suture Distance (2mm vs 5mm) N/A
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A